Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs-Reference-Cited by-同舟云学术

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

Published:2010-06 Issue:6 Volume:39 Page:425-441
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Bergman Gert J.D.,Hochberg Marc C.,Boers Maarten,Wintfeld Neil,Kielhorn Adrian,Jansen Jeroen P.

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference32 articles.

1. Guidelines for the management of rheumatoid arthritis: 2002 update;Arthritis Rheum,2002

2. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001);Ledingham;Rheumatology,2005

3. Guide to the methods of technology appraisal,2008

4. Combination of direct and indirect evidence in mixed treatment comparisons;Lu;Stat Med,2004

5. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses;Song;Br Med J,2003

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct fibroblast functions associated with fibrotic and immune-mediated inflammatory diseases and their implications for therapeutic development;F1000Research;2024-01-10

2. Real-world retention rates of biologics in patients with rheumatoid arthritis;Scientific Reports;2023-12-01

3. Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis;International Immunopharmacology;2023-09

4. Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis;Advances in Rheumatology;2023-07-06

5. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects;Frontiers in Pharmacology;2023-04-04